Blue Jet Healthcare Limited — PPTs, 04-11-2025: Investor Presentation

Blue Jet Healthcare reported robust half-year financial results, with H1 FY26 revenue up 40% year-on-year to 520.2 Cr and PAT rising 49% to 143.3 Cr (EPS Rs 8.3). However, Q2 FY26 saw a revenue decline of 20.5% YoY to 165.5 Cr and PAT dip 10.6% to 52.1 Cr (EPS Rs 3.0), mainly due to channel inventory de-stocking in the Pharma Intermediates (PI) segment. Gross Margin in Q2 improved significantly to 65%.

Recent developments include the launch of a new iodinated contrast media intermediate and strong order book for MRI contrast media. The company also paid 42 Cr for 102 acres of land near Vizag and incurred 82 Cr capex for Mahad backward integration.

Strategic focus involves expanding production capacity, boosting R&D investment, and leveraging customer relationships to enter new PI & API areas. Blue Jet also aims to forward integrate into more advanced contrast media intermediates, moving up the value chain. Free cash and treasury investments total 341.3 Cr, enhanced by working capital unlocking.